On Demand: Cell & Gene Day
As a wave of up-and-coming cell and gene therapies eye the path to approval soon, a combination of uncertainties threatens the waters ahead. A lack of talent, shortage of manufacturing, standardization, and shifting infrastructure are just the beginning of a range of potential issues.
Join Endpoints News and Precision ADVANCE for Cell & Gene Day, a free virtual event on August 24, from 12:00-4:00 PM ET where we convene three distinguished panels of experts to find out where the field stands today and explore funding, development, and launch strategies to smooth out the ride to commercialization. You will hear from successful innovators from each facet of the CGTx landscape including executives from Blackstone, Flagship Pioneering, Monograph Capital, Alliance for Regenerative Medicine, Satellite Bio, Cellevolve Bio, and more.
Publication: Rare Disease on Payer’s Minds
As payers began to deal with increased costs in 2021 due to deferred care during the COVID-19 pandemic, they still continued to grapple with the prospect of the impact of future gene therapies’ cost, according to industry experts. Precision’s Phil Cyr (SVP) and Erin Lopata (VP, Access Experience Team) weigh in on new ways to pay for the potential flood of gene therapies for rare diseases brewing in the pipeline.
On Demand Panel: Meeting on the Med, 2022
Panel Discussion: The Next Normal: Predictions for the Future of Advanced Medicines
Precision attended this year’s Meeting on the Med conference from April 20 – 22nd in Barcelona, Spain. On April 20th our team of experts lead meaningful discussions throughout, providing insights into the clinical development, manufacturing, and commercialization of cell and gene therapies. This panel discussion focused on the sector’s continued success and challenges that lie ahead in research and development, manufacturing, regulatory, pricing, and reimbursement. Watch our panel of industry experts discuss the future of advanced medicines with emerging technologies like gene editing, non-viral delivery methods, and allogeneic cell therapies.
Moderated by Anshul Mangal (President of Project Farma / Precision ADVANCE) this discussion will feature insights from Robert Ang (President & CEO Vor Biopharma), Deb Phippard (CSO Precision for Medicine / Precision ADVANCE), Brent Rice (SVP & CCO Autolus Therapeutics) and Johanna Rossell (CCO Enzyvant Therapeutics).
On-Demand: Public Markets’ Impact on Manufacturing Advanced Therapies
Commercial viability for cell and gene therapy requires the right approach to manufacturing. This webinar, sponsored by Project Farma and Precision ADVANCE addressed public market trends and their impact on the decision to manufacture cell and gene therapies internally or with an external supplier such as a CDMO. Our panel of experts discussed their organizations’ pipeline, the advanced therapy investment landscape, and the regulatory, manufacturing, and commercial requirements for successfully bringing an advanced therapy to market.
Publication: Value of a Cure for Sickle Cell Disease in Reducing Economic Disparities
If a genetic therapy was created to cure sickle cell disease, how might this affect the productivity and earnings of an individual with the disease? How might this change also affect wider economic disparities? PRECISIONheor’s Marlon Graf (Senior Research Economist), Rifat Tuly (Research Scientist), and Jeff Sullivan (Senior Director) recently constructed a model to answer these impactful questions.
Click here to learn more about the model and the team’s findings.